Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Azelastine Hydrochloride

FDA-approved product (spray, metered, nasal), marketed as Astelin, Astepro, Astepro Allergy and 5 more.

Registered studies
48
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Azelastine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Allergic conjunctivitis
  • Allergic disease
  • Allergic rhinitis
  • Eye allergy
  • Nasal congestion
  • Rhinitis, Allergic, Perennial
  • Seasonal allergic rhinitis
  • Vasomotor rhinitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antiallergic agents, excl. corticosteroids; Other antihistamines for systemic use; Other antiallergics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

48registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Azelastine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Azelastine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Single Dose Pharmacokinetics of Intranasal Fluticasone Delivered by a Fixed Combination With Azelastine (MP29 02) in Comparison to Two Different Fluticasone Nasal Sprays

    NCT01194622 · start 2010-08

    Registered record
    Registry ID
    NCT01194622
    Conditions
    Allergic Rhinitis
    Interventions
    Azelastine, Fluticasone; Fluticasone mono; Fluticasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-08
    Completion
    2010-10
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis
    InterventionAzelastine, Fluticasone; Fluticasone mono; Fluticasone
    PhasePhase 1
    Registry statusCompleted

  • A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis

    NCT01018862 · start 2009-11

    Registered record
    Registry ID
    NCT01018862
    Conditions
    Perennial Allergic Rhinitis
    Interventions
    Azelastine hydrochloride nasal spray 0.15%; Azelastine hydrochloride nasal spray 0.10%; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-11
    Completion
    2011-04
    Enrolment
    489

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPerennial Allergic Rhinitis
    InterventionAzelastine hydrochloride nasal spray 0.15%; Azelastine hydrochloride nasal spray 0.10%; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis

    NCT00979615 · start 2009-09

    Registered record
    Registry ID
    NCT00979615
    Conditions
    Vasomotor Rhinitis
    Interventions
    Olopatadine HCL (Patanase) Nasal Spray, 0.6%; Azelastine HCl (Astelin) Nasal Spray, 137 mcg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-09
    Completion
    Not recorded
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVasomotor Rhinitis
    InterventionOlopatadine HCL (Patanase) Nasal Spray, 0.6%; Azelastine HCl (Astelin) Nasal Spray, 137 mcg
    PhasePhase 4
    Registry statusCompleted

  • A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

    NCT00883168 · start 2009-04

    Registered record
    Registry ID
    NCT00883168
    Conditions
    Seasonal Allergic Rhinitis
    Interventions
    Placebo; azelastineHcl; fluticasone propionate; azelastine Hcl/fluticasone propionate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-04
    Completion
    2009-07
    Enrolment
    1,791

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasonal Allergic Rhinitis
    InterventionPlacebo; azelastineHcl; fluticasone propionate; azelastine Hcl/fluticasone propionate
    PhasePhase 3
    Registry statusCompleted

  • Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid

    NCT00845195 · start 2009-03

    Registered record
    Registry ID
    NCT00845195
    Conditions
    Seasonal Allergic Rhinitis
    Interventions
    Olopatadine HCl Nasal Spray, 0.6%; Azelastine HCl Nasal Spray, 0.1%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-03
    Completion
    Not recorded
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasonal Allergic Rhinitis
    InterventionOlopatadine HCl Nasal Spray, 0.6%; Azelastine HCl Nasal Spray, 0.1%
    PhasePhase 4
    Registry statusCompleted

  • A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

    NCT00824473 · start 2008-12

    Registered record
    Registry ID
    NCT00824473
    Conditions
    Seasonal Allergic Rhinitis
    Interventions
    Placebo; 0.15% azelastine hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-12
    Completion
    2009-02
    Enrolment
    506

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasonal Allergic Rhinitis
    InterventionPlacebo; 0.15% azelastine hydrochloride
    PhasePhase 3
    Registry statusCompleted

  • Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis

    NCT00772304 · start 2008-10

    Registered record
    Registry ID
    NCT00772304
    Conditions
    Allergic Rhinitis
    Interventions
    Olopatadine 0.6% / Azelastine 137 mcg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-10
    Completion
    Not recorded
    Enrolment
    102

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis
    InterventionOlopatadine 0.6% / Azelastine 137 mcg
    PhasePhase 4
    Registry statusCompleted

  • A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

    NCT00740792 · start 2008-08

    Registered record
    Registry ID
    NCT00740792
    Conditions
    Seasonal Allergic Rhinitis
    Interventions
    azelastine HCl/fluticasone propionate; azelastine Hcl; fluticasone propionate; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-08
    Completion
    2008-11
    Enrolment
    776

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasonal Allergic Rhinitis
    Interventionazelastine HCl/fluticasone propionate; azelastine Hcl; fluticasone propionate; placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

    NCT00651118 · start 2008-03

    Registered record
    Registry ID
    NCT00651118
    Conditions
    Seasonal Allergic Rhinitis
    Interventions
    Placebo; azelastine Hcl; azelastineHcl / fluticasone propionate; fluticasone propionate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-03
    Completion
    2008-07
    Enrolment
    832

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasonal Allergic Rhinitis
    InterventionPlacebo; azelastine Hcl; azelastineHcl / fluticasone propionate; fluticasone propionate
    PhasePhase 3
    Registry statusCompleted

  • A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis

    NCT00612118 · start 2008-02

    Registered record
    Registry ID
    NCT00612118
    Conditions
    Allergic Rhinitis; Rhinitis, Allergic, Seasonal
    Interventions
    GSK256066; azelastine hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-02
    Completion
    2008-05
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis; Rhinitis, Allergic, Seasonal
    InterventionGSK256066; azelastine hydrochloride
    PhasePhase 2
    Registry statusCompleted

  • A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

    NCT00660517 · start 2007-12

    Registered record
    Registry ID
    NCT00660517
    Conditions
    Seasonal Allergic Rhinitis
    Interventions
    MP29-02; azelastine Hcl; fluticasone propionate; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-12
    Completion
    2008-04
    Enrolment
    607

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasonal Allergic Rhinitis
    InterventionMP29-02; azelastine Hcl; fluticasone propionate; placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

    NCT00660829 · start 2007-12

    Registered record
    Registry ID
    NCT00660829
    Conditions
    Seasonal Allergic Rhinitis
    Interventions
    Placebo; 0.15% Azelastine Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-12
    Completion
    2008-04
    Enrolment
    536

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasonal Allergic Rhinitis
    InterventionPlacebo; 0.15% Azelastine Hydrochloride
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies

    NCT00719862 · start 2007-08

    Registered record
    Registry ID
    NCT00719862
    Conditions
    Seasonal Allergic Rhinitis
    Interventions
    Placebo nasal spray; 0.15% azelastine hydrochloride Nasal Spray
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-08
    Completion
    2007-11
    Enrolment
    481

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasonal Allergic Rhinitis
    InterventionPlacebo nasal spray; 0.15% azelastine hydrochloride Nasal Spray
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies

    NCT00720278 · start 2007-08

    Registered record
    Registry ID
    NCT00720278
    Conditions
    Seasonal Allergic Rhinitis
    Interventions
    0.15% azelastine hydrochloride 1644 mcg daily; 0.1% azelastine hydrochloride 1096 mcg daily; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-08
    Completion
    2007-11
    Enrolment
    526

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasonal Allergic Rhinitis
    Intervention0.15% azelastine hydrochloride 1644 mcg daily; 0.1% azelastine hydrochloride 1096 mcg daily; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis

    NCT00720382 · start 2007-03

    Registered record
    Registry ID
    NCT00720382
    Conditions
    Perennial Allergic Rhinitis
    Interventions
    0.15% azelastine hydrochloride; Mometasone furoate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-03
    Completion
    2008-07
    Enrolment
    703

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPerennial Allergic Rhinitis
    Intervention0.15% azelastine hydrochloride; Mometasone furoate
    PhasePhase 3
    Registry statusCompleted